ReiThera Announces Preliminary Phase 2 Data from its COVID-19 Vaccine Candidate
GRAd-COV2 is well tolerated and induces clear immune responses in trial subjects Antibody response against the SARS-CoV-2 spike protein generated in over 93% of volunteers after first dose, [...]
